Radoslaw Rudz posted this:
Licensing Manager at Centre Technology Transfer CITTRU
Guillermo Rodríguez posted this:
R&D Manager at Biótica, Bioquímica Analítica,S.L.
Universidad de Alcalá-OTRI posted this:Compounds for the treatment of Leishmania infectionsThe research group Heterobetainas of the University of Alcalá presents the preparation and uses of a series of compounds that act as bioactive agents against the Leishmania parasite and as therapeutic agents in the treatment of this disease, in both, its visceral (LV) version and in the mucocutaneous one (CML). The group is looking for pharmaceutical companies interested in manufacturing an active ingredient for the formulation of a leishmanicidal drug based on these compounds. The group proposes the signing of a patent license agreement, a collaboration agreement or a commercial agreement with technical
Universidad de Alcalá-OTRI posted this:Endothelial microvesicles with microbicidal effect for the preparation of a medicament or for a direct useThe research group "Cell damage associated with senescence" of the University of Alcalá presents the microbicidal capacity of endothelial microvesicles. These vesicles destroy the main pathogens involved in sepsis and even strains derived from them resistant to multiple antibiotics. They have also been shown to be effective against the biofilms that form these microorganisms. The group seeks to reach licensing agreements, cooperation or commercial agreements with technical assistance, with pharmaceutical companies interested in the design of new medicines.
Lucas Montes posted this:
Technology Transfer Advisor at University of Granada (OTRI)
University of Vigo posted this:Method for the sequential immunochemical evaluation on a same biological sample of NCAM (Neural Cell Adhesion Molecule) protein and its PolySialic Acid (PSA) tail, by western blot coupled to chemiluminiscence detection.The method optimizes the expression assays of PSA-NCAM isoforms in biological samples available in small quantities or restricted (as is the case of human specimens, for example). It improves quantitative and qualitative performance of PSA-NCAM analysis by western blot.
University of Vigo posted this:Valorization of whey and vinasses by producing antimicrobial extracts using biotechnological processesThis invention is based on the production of antimicrobial extracts with potential application against pathogenic microorganisms. The biotechnological production of antimicrobial metabolites was carried out using Lactobacillus plantarum strains. Two industrial wastes, whey, and wine distilled lees (or vinasses) were assayed in order to make the process economically competitive with regard to the chemical one. The extracts are mainly composed by lactic acid, 3-phenyllactic and bacteriocins. Whey was enzymatically hydrolyzed and the solutions were fermented sequentially or simultaneously. The bioprocesses were carried out continuously or discontinuously
RAMOT at Tel Aviv University Ltd. posted this:A novel behavioral bioassay for preclinical testing and characterization of CNS agentsOur team, including zoologists, statisticians, and computer scientists have developed a new hi-res bioassay for preclinical testing and characterization of CNS agents, extracting key animal-centered parameters of behavior via computerized tracking and measurement of free exploration. The features that distinguish our system and method from other existing systems and methods are: elaborate data preparation for analysis and a methodology that secures replicability of results across laboratories, and exposes active management of kinematic variables. Our measured parameters are carefully designed, animal-centered building blocks of behavior. They are selected on the basis of an in-depth understanding of the mouse’s functional world. These quite unexpected and unusual parameters reflect the animal’s cognitive and emotional state and its information processing capacity; therefore they are most prone to be affected by drugs that act on respective CNS structures that mediate these states. Unlike all other existing systems we expose and quantify the rich and highly organized developmental dynamics of self regulated behavioral growth. The dynamics of this process before and after genetic manipulation and/or pharmacological treatment can now be readily measured by our system, articulating the effects of potential CNS drugs on behavioral growth and decay processes. Project ID : 2-2009-11
RAMOT at Tel Aviv University Ltd. posted this:Oral Mucosa-derived Stem Cells: A Unique Population for the Prevention and Treatment of Ischemic Heart FailureStem cells (SC) are considered crucial building blocks for any regenerative strategy. Adult oral mucosa (OM) is a unique source for generating adult pluripotent stem cell (OPSC) populations. This uniqueness consists in the fact that 95% of the OM whole populations in culture (1st – 8th passages) express markers of embryonic and mesenchymal SC. Thus, in contradistinction to known sources which comprise very low numbers of SC, OPSC generation for clinical use is simple and cost effective and does not require cumbersome cost-consuming purification steps. The general objective is to lay the foundation for the development of a variety of products based on the pluripotency and simple and cost effective generation of billions of OPSC. The major aim of the proposed project is to develop a product for the treatment of ischemic heart failure (IHF). This product which will serve as a proof of concept was selected based on medicals needs, market cap and time to market. The specific aims of the proposal are: 1. To develop a cardiac product aimed at treating ischemic heart failure (IHF). The aim is to test the safety and therapeutic effect of OPSC on experimental IHF in a minipig model. 2. To strengthen the intellectual property by fully characterizing the profile of OPSC. The prevalence of IHF continuously increases (1 million new cases every year in the western world) and currently the market cap is estimated in the range of billions. Project ID : 10-2011-260
RAMOT at Tel Aviv University Ltd. posted this:Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal ModelCerebral amyloid angiopathy (CAA) is due to amyloid accumulation in the vessel walls leading to hemorrhagic stroke, and cognitive impairment. There are no available treatments to specifically reduce the risk of CAA. In this research we aim to assess brain tissue damage and cognitive impairment resulting from CAA in animal model and to investigate a novel approach to immune therapy. Methods: We have shown that nasal vaccination with a proteosome adjuvant (Protollin) that is well tolerated in humans, decreases amyloid plaques in an Alzheimer’s disease mouse model. It was recently reported that an overexpression of TGF-?1 under the control of an astrocyte promoter GFAP in mice results in CAA. TGF-?1 mice were nasally treated with Protollin on a weekly basis starting at the age of 13 months for three months. Following treatment animals were subjected for MRI and cognition analysis. Results: Here we show that nasal Protollin activates perivascular macrophage and potently decreases vascular amyloid in TGF-?1 mice. Using MRI we found that while PBS treated animals showed a significant enlargement of the lateral ventricles area, Protollin prevents further brain damage and prevents pathological changes in the blood-brain barrier. Vascular risk factors have been found to be associated with vascular dementia. Using an object recognition test and Y-maze, we found significant improvement in cognition with the Protollin treated group. Interpretation :Our study demonstrates that activation of macrophages by Protollin is a novel approach to reduce microhemorrhage, prevent stroke and improve cognition in a model of cerebral amyloid angiopathy. Project ID : 10-2011-259
Centre Technology Transfer CITTRU posted this:Novel antiviral agent based on modified chitosanThe subject of the new invention is new drug developed by researchers of the Jagiellonian University is intended for treatment and prevention of viral infections caused by coronaviruses in humans, including respiratory diseases manifested by impaired respiratory function – application in biotechnology & medicine.
Small and Medium Enterprise
Creative Proteomics posted this:Proteomic ServiceCreative Proteomics specializes in a full range of services to support various proteome-related researches from identification of single proteins to large-scale proteomic studies. We have one of the most advanced proteomics platforms in the world and our staff scientists are experienced proteomics professionals.
Centre Technology Transfer CITTRU posted this:Manganese-lactoferrin complex stimulating the growth of probiotic bacteriaThe subject of the offer is manganese-lactoferrin complex with properties stimulating the growth of probiotic bacteria in digestive system. Possible applications of the invention include prevention and treatment of bacterial infections (including sepsis in newborns), chronic inflammatory bowel diseases, dietary supplementation in prevention of bacterial infections and some other indications.
Centre Technology Transfer CITTRU posted this:Staphylococcus pseudintermedius & bacteriocins – various applicationsThe subject of the present offer is new bacterial strain Staphylococcus pseudintermedius Sp222, isolated from dog pathologic dermal lesions. The offer includes also peptide and protein bacteriocins produced by S. pseudintermedius Sp222. These bacteriocins exhibit a broad spectrum of biological activities: - bacteriocin BacSp222 is able to kill a variety of Gram+ bacteria strains, including the methicillin resistant S. aureus (MRSA) strain. It is also cytotoxic towards selected eukaryotic cells and is resistant to action of proteolytic enzymes (either eukaryotic or prokaryotic) as well as to high temperature. The biological activity of BacSp222 is sustained even after limited fragmentation of its molecule by chemical reagents; - lysostaphin Sp222 has an ability to effectively lyse (and, in consequence, to kill) the cells of Gram+ bacteria.
Universidad de Alicante posted this:Novel photobioreactor for mass cultivation of microalgaeThe main innovation of this invention is: • This novel photobioreactor combines the mechanism of a bubble column with the air-lift type for higher biomass production than that obtained for both systems separately.